주문제작 서비스 문의
찾으시는 제품이 저희 사이트에 없으신가요? 단백질 주문 제작 서비스를 이용해보세요!
주문제작 서비스 문의 >>
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 94.7 kDa. The protein migrates as 110-140 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human EGF R, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human EGF R, Fc Tag (Cat. No. EGR-H5252) is more than 90% and the molecular weight of this protein is around 220-260 kDa verified by SEC-MALS.
Immobilized Human EGF, Mouse IgG2a Fc Tag (Cat. No. EGF-H525b) at 2 μg/mL (100 μL/well) can bind Human EGF R, Fc Tag (Cat. No. EGR-H5252) with a linear range of 0.3-5 ng/mL (QC tested).
Immobilized Human EGF R, Fc Tag (Cat. No. EGR-H5252) at 1 μg/mL (100 μL/well) can bind Cetuximab with a linear range of 0.1-2 ng/mL (Routinely tested).
ACROBiosystems는 생체 활성이 높은 균질한 CD3 δ/CD3 ε 및 CD3 γ/CD3 ε 단백질을 개발하여 이중특이 항체를 치료제로의 임상 개발을 가속시킵니다.
오가노이드 툴 박스는 약물 개발 프로젝트의 진행을 가속할 수 있는 레디메이드 오가노이드와 오가노이드 분화 툴 키트 및 다양한 서비스를 포함하는 오가노이드 솔루션 모음입니다.
항체 및 번역 후 변형(PTMs)의 특성 분석을 위해, ACROBiosysyems는 IdeS, SpeB, EndoH, and Endo S proteases 계열의 효소를 개발하였습니다.
고품질 GMP 등급 사이토카인 IL-15,IL-7, IL-21 등 제품은 신속한 임상/신약승인신청을 위해 개발된 것입니다.
50+ car-t의 인기 타겟을 커버하고, car 발현 검사를 위해 특별히 설계된 항원 단백질은 스트림 검증을 통해 고특이성 car 발현을 검출할 수 있으며, 고 배치간 일관성을 가지고 있다.pe/fi표기 단백질로 한 단계 염색하면 고특이성, 무 백그라운드로 car 발현 검사를 검사할 수 있습니다.
GMP 등급 사이토카인. 고품질 세포 활성화 및 확장 시약. 유전자 편집 시약, 효소 CAR 검사 시약 등 제품. 세포 및 유전자 요법 고객님에게 포괄적인 솔루션을 제공하고 초기 약물 발견에서 임상 연구에 이르기까지 모든 단계에서 귀하와 동반하겠습니다.
cd20, claudin18.2, cd133, gprc5d, ccr5, ccr8을 포함한 안정적이고 활성이 높은 전장 다중 막관통 단백질은 면역, elisa, spr, bli, 세포 실험, car 양성률 검사 등에 광범위하게 사용된다. vlp, 스케일제거제, nanodisc의 다양한 기술 플랫폼은 다중 막관통 단백질을 목표로 하는 약물 연구에 도움을 준다.
현재 이미 알려진 거의 대부분의 면역 체크 포인트 분자를 포함하여 다양한 레벨과 물종을 제공하여 고객이 선택할수 있도록 하고있다. 천연중합체 형식은 mals를 통해 검증되었고 생물활성은 elisa/spr/bli/facs 등을 통해 검증되었으며 또한 biotin/fitc 표지는 높은 처리량을 가진 항체를 선별하는데 편리하다.
ACROBiosystems는 ADC약물의 연구개발을 돕기 위해 노력하고 있으며, 다양한 인기 타겟에 서로 다른 종, 다른 라벨의 제품을 개발했으며, 높은 순도, 높은 친화력 등 특징을 가지고 있으며, 면역, 항체 선택, spr, 세포 활성 검사 및 기타 실험에 적합하고, 해당 protocol을 무료로 제공합니다.
Fc 수용체 단백질은 모든 분자를 포함하고 있을 뿐만 아니라, 일반적인 돌연변이와 바이오틴 표기 종류을 포함하고 있어 고객들이 단일 클론 항체 개발을 가속화할 수 있다.
포괄적으로 풍부한 사이토카인 표적 단백질은 HEK293 진핵생물 시스템에 의해 발현되며 천연 구조에 더 가깝다. 고순도는 SDS-PAGE/HPLC/MALS에 의해 검증된다. 높은 생물학적 활성이 ELISA/SPR/BLI에 의해 검증된다. 배치간 일관성이 우수하여 항체 면역, 스크리닝 및 품질 관리 과정에 적합하다.
Aneuro는 ACROBiosystems가 뇌과학 연구에 초점을 맞춘 제품 라인으로서 치료 및 진단 연구 단백질, PFFs와 재조합 신경 인자 등 뇌과학 연구 분야에 중요한 단백질 제품을 제공하여 뇌과학 연구에 도움이 된다.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Panitumumab | ABX-0303; E7.6.3; AMG-954; ABX-EGF; ABX-10221 | Approved | Amgen Inc | Vectibix | United States | Colorectal Neoplasms | Amgen Inc | 2006-09-27 | Colonic Neoplasms; Exanthema; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis; Glioma; Carcinoma, Squamous Cell; Lung Neoplasms; Adenoma, Pleomorphic; Colorectal Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Neoplasms; Malignant Carcinoid Syndrome; Salivary Gland Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma; Kidney Neoplasms; Solid tumours | Details |
Cetuximab | IMC-C255; BMS-564717; EMD-271786; C-255; GT-MAB-5.2; ch-225; LY-2939777; NSC-714692 | Approved | Bristol-Myers Squibb Company, Eli Lilly And Company, Merck Serono | 爱必妥, Erbitux | United States | Colorectal Neoplasms | Imclone Gmbh | 2004-02-12 | Carcinoma, Squamous Cell; Oropharyngeal Neoplasms; Neuralgia; Colorectal Neoplasms; Peritoneal Neoplasms; Glioma; Lung Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Laryngeal Neoplasms; Nasopharyngeal Carcinoma; Adenocarcinoma, Mucinous; Fallopian Tube Neoplasms; Complex Regional Pain Syndromes; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Gastrointestinal Neoplasms; Precancerous Conditions; Pancreatic Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Pain; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplastic Cells, Circulating; Glioblastoma; Neoplasms; Hypopharyngeal Neoplasms; Neoplasms, Squamous Cell; Colonic Neoplasms; Chordoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Dacomitinib | PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 | Approved | Pfizer Inc | Vizimpro | United States | Carcinoma, Non-Small-Cell Lung | Pfizer Inc | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Penile Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Solid tumours; Brain Neoplasms; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms | Details |
Recombinant Human Epidermal Growth Factor Derivative Eye Drops (Shenzhen Wastin Genetech) | Approved | Shenzhen Watsin Genetech Ltd | 金因舒, GeneSoft | Mainland China | Corneal Diseases | Shenzhen Watsin Genetech Ltd | 2004-01-21 | Corneal Diseases | Details | |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lung Neoplasms; Brain metastases; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neuroma, Acoustic; Meningioma; Neurilemmoma | Details |
Recombinant epidermal growth factor gel (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易孚 | Mainland China | Skin Ulcer; Burns | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-12-23 | Skin Ulcer; Burns | Details | |
Erlotinib Hydrochloride | CP-358774-01; RO-0508231; NSC-718781; CP-358774; RG-1415; OSI-774; R-1415 | Approved | Genentech Inc | Tarceva, 特罗凯 | EU | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Roche Registration Gmbh | 2004-11-18 | Head and Neck Neoplasms; Kidney Neoplasms; Cystadenocarcinoma; Solid tumours; Ovarian Neoplasms; Liver Neoplasms; HIV Infections; Adenomatous Polyposis Coli; Neoplasm Recurrence, Local; Ependymoma; Brenner Tumor; Rhabdomyosarcoma; Medulloblastoma; Leukemia, Promyelocytic, Acute; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Mucinous; Anus Neoplasms; Esophageal Neoplasms; Esthesioneuroblastoma, Olfactory; Granuloma, Lethal Midline; Carcinoma, Basal Cell; Rectal Neoplasms; Cystadenocarcinoma, Serous; Polycythemia Vera; Anaplasia; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Nasopharyngeal Neoplasms; Adenocarcinoma of Lung; Fibrosis; Carcinoma, Verrucous; Liver Cirrhosis; Leukemia, Myelomonocytic, Chronic; Mesothelioma; Urinary Bladder Neoplasms; Pancreatic Intraductal Neopl | Details |
Afatinib Dimaleate | BIBW-2992-MA2; BIBW-2992 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok | United States | Carcinoma, Non-Small-Cell Lung | C.H. Boehringer Sohn Ag & Co. Kg | 2013-07-12 | Esophageal Squamous Cell Carcinoma; Urethral Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Rhabdomyosarcoma; Multiple Myeloma; Liver Diseases; Chordoma; Urinary Bladder Neoplasms; Neoplasms, Squamous Cell; Glioblastoma; Neuroectodermal Tumors; Neoplasms; Renal Insufficiency; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Solid tumours; Head and Neck Neoplasms | Details |
Necitumumab | LY-3012211; IMC-11F8 | Approved | Eli Lilly And Company | Portrazza | United States | Carcinoma, Non-Small-Cell Lung | Eli Lilly And Co (Ireland) Ltd | 2015-11-24 | Solid tumours; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Recombinant epidermal growth factor (Shanghai Haohai ) | Approved | Shanghai Haohai Biological Technology Co Ltd | 康合素 | Mainland China | Burns | Shanghai Haohai Biological Technology Co Ltd | 2001-01-01 | Burns | Details | |
PX-070101 | PX-070101 | Approved | Praxis Pharmaceuticals | Colombia | Diabetic Foot | Praxis Pharmaceuticals | 2015-07-01 | Diabetic Foot | Details | |
Recombinant epidermal growth factor drop (Pavay Gene Pharmaceutical) | Approved | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 易贝 | Mainland China | Corneal Diseases | Guilin Huanuowei Gene Pharmaceutical Co Ltd | 2002-04-12 | Corneal Diseases; Xerophthalmia | Details | |
Recombinant epidermal growth factor (Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals) | Approved | Praxis Pharmaceuticals, Center For Genetic Engineering And Biotechnology | Heberprot-P | Cuba | Diabetic Foot | null | 2007-09-01 | Diabetic Foot | Details | |
Nimotuzumab | KI-0502; KI-0501; DE-766; YMB-1000; OSAG-101; h-R3; TheraCIMh-R3; OSAG-10 | Approved | Center Of Molecular Immunology, Cimym Biosciences | Theraloc, BIOMAb-EGFR, TheraCIM, 泰欣生, CIMAher | India | Nasopharyngeal Neoplasms; Head and Neck Neoplasms | null | 2006-07-21 | Nasopharyngeal Neoplasms; Uterine Cervical Neoplasms; Esophageal Diseases; Carcinoma, Non-Small-Cell Lung; Glioma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Head and Neck Neoplasms; Pancreatic neuroendocrine tumors (pNET); Pancreatic Neoplasms; Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Metastatic breast cancer; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Lazertinib | YH-25448; JNJ-73841937; JNJ-1937; GNS-1480 | Approved | Oscotec Inc, Janssen Biotech Inc, Yuhan Corp | Leclaza | South Korea | Carcinoma, Non-Small-Cell Lung | Yuhan Corp | 2021-01-18 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung | Details |
Amivantamab | CNTO4424; CNTO-4424; JNJ-61186372; JNJ-372; JNJ-6372 | Approved | Genmab A/S | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Recombinant epidermal growth factor biosimilar (Elea) | r-hu-EGF | Approved | Elea | Argentina | Diabetic Foot; Burns | Elea | 2015-01-01 | Diabetic Foot; Burns | Details | |
Epidermal growth factor biosimilar (RAS Lifesciences) | Approved | Ras Lifesciences | India | Ras Lifesciences | 2012-10-01 | Details | ||||
Nepidermin | DWP-401 | Approved | Daewoong Pharmaceutical Co Ltd | Easyef | South Korea | Alopecia; Diabetic Foot | Daewoong Pharmaceutical Co Ltd | 2001-01-01 | Diabetic Foot; Alopecia; Dry Eye Syndromes | Details |
Gefitinib | ZD-1839 | Approved | Astrazeneca Pharmaceutical Co Ltd | 易瑞沙, Iressa | Japan | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2002-07-05 | Leukemia, Myeloid, Acute; Carcinoma, Adenosquamous; Prostatic Neoplasms; Gastrinoma; Breast Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Gliosarcoma; Astrocytoma; Carcinoma, Mucoepidermoid; Carcinoma, Squamous Cell; Lung Neoplasms; Neoplasms, Neuroepithelial; Brain Neoplasms; Glioma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Carcinoma, Hepatocellular; Somatostatinoma; Gastrointestinal Neoplasms; Breast Neoplasms, Male; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Adenocarcinoma; Neoplasms; Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoid Tumor; Vipoma; Insulinoma; Carcinoma; Stomach Neoplasms; Abdominal Neoplasms; Carcinoma, Renal Cell; Head and Neck Neoplasms; Skin Neoplasms; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Adenocarcinoma of Lung; Carcinoma, Transitional Cell; | Details |
Cetuximab biosimilar (CinnaGen) | Approved | Cinnagen | Iran | Colorectal Neoplasms | Cinnagen | 2017-01-01 | Colorectal Neoplasms | Details | ||
Recombinant epidermal growth factor (Bharat Biotech) | REGEN-D 60; REGEN-D 150 | Approved | Bharat Biotech International Ltd | India | Diabetic Foot; Burns | Bharat Biotech International Ltd | 2005-01-01 | Diabetic Foot; Burns | Details | |
Sunvozertinib | DZD-9008 | Approved | Dizal (Jiangsu) Pharmaceutical Co Ltd | 舒沃哲 | Mainland China | Carcinoma, Non-Small-Cell Lung | Dizal (Jiangsu) Pharmaceutical Co Ltd | 2023-08-22 | Lymphoma, B-Cell; Hepatic Insufficiency; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung | Details |
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Brain metastases; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Meningeal Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Multiple Myeloma; Esophageal adenocarcinoma; Thyroid Neoplasms; Glioma; Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma; Adenocarcinoma of Lung; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Carcinoma, Transitional Cell; Skin Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | Details |
Cetuximab sarotalocan | RM-1929; ASP-1929 | Approved | Aspyrian Therapeutics | Akalux | Japan | Head and Neck Neoplasms | Rakuten Medical Inc | 2020-09-25 | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
Icotinib Hydrochloride | BPI-2009H; BPI-2009C | Approved | Betta Pharmaceuticals Co Ltd | 凯美纳, Conmana | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2011-06-07 | Carcinoma, Adenosquamous; Neuroma, Acoustic; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Breast Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Psoriasis; Adenocarcinoma of Lung; Neurofibromatosis 2; Bronchial Neoplasms; Stomach Neoplasms; Esophageal Neoplasms | Details |
Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | United States | Breast Neoplasms | Novartis Pharma Ag | 2007-03-13 | Gallbladder Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Bile Duct Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Endometrial Neoplasms; Neoplasms, Gonadal Tissue; Lung Neoplasms; Carcinoma, Squamous Cell; Glioma; Laryngeal Neoplasms; Prostatic Neoplasms; Brain metastases; Lymphoma; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Tongue Neoplasms; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Carcinoma, Hepatocellular; Neoplasm Metastasis; Glioblastoma; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Abdominal Neoplasms; Salivary Gland Neoplasms; Medulloblastoma; Carcinoma, Verrucous; Neoplasms; Neurofibromatosis 2; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Oligodendroglioma; Carcinoma, Adenoid Cystic; Breast Neoplasms; B | Details |
Recombinant Human Epidermal Growth Factor Derivative (Shenzhen Wastin Genetech) | rEGF | Approved | Shenzhen Watsin Genetech Ltd | 金因肽, GeneTime | Mainland China | Wounds and Injuries | Shenzhen Watsin Genetech Ltd | 2001-01-01 | Wounds and Injuries | Details |
Recombinant human EGF conjugated vaccine | Approved | Biotech Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | ||||||
Mouse epidermal growth factor (Hangzhou Tianmushan Pharmaceutical) | Approved | Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd | 一夫 | Wounds and Injuries | Details | |||||
Neratinib Maleate | CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 | Approved | Pfizer Pharmaceuticals Ltd (China) | Nerlynx, 贺俪安 | United States | Breast Neoplasms | Puma Biotechnology Inc | 2017-07-17 | Solid tumours; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cetuximab biosimilar (R-Pharm) | RPH-002 | Phase 3 Clinical | R-Pharm | Head and Neck Neoplasms; Pancreatic Neoplasms | Details |
D2C7-based immunotoxins (Duke University) | D2C7-IT; scds-D2C7 -PE38KDEL; D2C7-(scdsFv)-PE38 KDEL | Phase 1 Clinical | Istari Oncology Inc, Duke University | Glioma | Details |
Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing) | Phase 3 Clinical | El Kendi Pharmaceuticals | Uterine Cervical Neoplasms | Details | |
CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Cetuximab-IRDye800CW (University Medical Center Groningen) | Phase 2 Clinical | Umcg The University Medical Center Groningen | Rectal Neoplasms; Lung Neoplasms; Penile Neoplasms | Details | |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
JNJ-26483327 | JNJ-26483327; MTKi-327; BGB-102 | Phase 2 Clinical | Johnson & Johnson | Solid tumours; Neoplasms; Macular Degeneration | Details |
HLX-42 | HLX-42; HLX42 | Phase 1 Clinical | Hanlin Biotechnology Co Ltd | Solid tumours; Neoplasms | Details |
HLX-35 | HLX-35 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
[111In]-FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
DAJH-1050766 | DAJH1050766; DAJH-1050766 | Phase 2 Clinical | Chengdu Diao Jiuhong Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung | Details |
BB-1705 | BB-1705 | Phase 1 Clinical | Bliss Biopharmaceutical (Hangzhou) Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
BNA-035 | BNA-035 | Phase 1 Clinical | Binacea Pharma Inc | Solid tumours | Details |
CM-93 | CM-93 | Phase 1 Clinical | Shanghai Crimson Pharmaceutical Co Ltd | Glioblastoma | Details |
REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours | Details |
WSD-0922 | WSD-0922; WSD0922 | Phase 1 Clinical | Wayshine Biopharm International Ltd | Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
ERAS-801 | ERAS-801 | Phase 1 Clinical | Regents Of The University Of California | Glioblastoma | Details |
EO-1001 | NT-113; APL-122 | Phase 2 Clinical | Edison Pharmaceuticals Inc | Neoplasms | Details |
Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) | Phase 2 Clinical | Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung | Breast Neoplasms | Details | |
HS-20117 | HS-20117; PM1080; PM-1080 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BC-3448 | BC3448; BC-3448 | Phase 1 Clinical | Wuxi Zhikang Hongyi Biological Technology Co Ltd | Solid tumours | Details |
AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 1 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms | Details |
Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
SGT-210 | SGT-210 | Phase 1 Clinical | Sol Gel Technologies Pte Ltd | Keratosis | Details |
Anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) | EGFR-806 | Phase 1 Clinical | Seattle Children'S Hospital | Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Retinoblastoma; Neuroblastoma; Sarcoma; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Sarcoma, Clear Cell; Rhabdomyosarcoma; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Desmoplastic Small Round Cell Tumor; Diffuse midline glioma; Solid tumours | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) | CmAb-(IL10)2; DF203; DF-203 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
Cetuximab biosimilar (Enzene Biosciences) | Clinical | Enzene Biosciences Ltd | Carcinoma, Squamous Cell | Details | |
BAY-2927088 | BAY-2927088; BAY2927088 | Phase 1 Clinical | Bayer AG | Carcinoma, Non-Small-Cell Lung | Details |
Diakine-DK2 10 (EGFR) | DK210; DK-2-10 | Phase 1 Clinical | Deka Biosciences Inc | Kidney Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
Nimotuzumab biosimilar (IBC Generium) | Phase 3 Clinical | International Biotechnology Center Generium Llc | Head and Neck Neoplasms | Details | |
MRG-003 | MRG003; MRG-003 | Phase 3 Clinical | Shanghai Miracogen Inc | Biliary Tract Neoplasms; Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Depatuxizumab mafodotin | ABT-414/806; ABT-414 | Phase 3 Clinical | Abbvie Inc | Glioblastoma; Gliosarcoma; Carcinoma, Squamous Cell; Glioma | Details |
JANX-008 | EGFR-TRACTr; JANX008; JANX-008 | Phase 1 Clinical | Janux Therapeutics Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
YK-029A | YK-029A; YK-209A; YK-209-A; YK-029-A | Phase 3 Clinical | Hainan Yuekang Biomedicine Co Ltd | Drug-Related Side Effects and Adverse Reactions; Carcinoma, Non-Small-Cell Lung | Details |
Varlitinib Ditosylate | SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 | Phase 3 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
AP-L1898 | AP-L1898; JS111; WJ-002 | Phase 2 Clinical | Suzhou Junjing Biomedical Technology Co Ltd, Wigen Biomedicine technology (Shanghai) Co Ltd, Shanghai Junshi Biosciences Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
CART-EGFR-IL13Ra2 | CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 | Phase 1 Clinical | University Of Pennsylvania | Glioblastoma | Details |
Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
HA121-28 | HA121-28; SYHA121-28 | Phase 3 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IBI334 | IBI334; IBI-334 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
Epitinib Succinate | HMPL-813 | Phase 1 Clinical | Hutchison Medipharma Ltd | Solid tumours; Neoplasms; Glioblastoma; Carcinoma, Non-Small-Cell Lung | Details |
Mefatinib | Phase 3 Clinical | Suzhou Maitai Bio-Technology Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) | QL-1105 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
Betatinib | TL-512 | Phase 1 Clinical | Aspedia Llc, Suzhou Teligene Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Panitumumab-IRDye800CW (Stanford University) | Phase 2 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Brain Neoplasms | Details | |
QL1203 | QL-1203 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Colorectal Neoplasms | Details |
LAVA-1223 | LAVA-1223; SGN-EGFRd2 | Phase 1 Clinical | Lava Therapeutics NV, Vu University Medical Center, Seagen Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
BBT-207 | BBT-207 | Phase 2 Clinical | Bridge Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung | Details |
BPI-361175 | BPI-361175 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Nazartinib | EGF-816; EGFRmut-TKI EGF816 | Phase 2 Clinical | Novartis Pharma Ag | Bronchial Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Sutetinib Maleate | Phase 2 Clinical | Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details | |
Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Liver Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
H-002 | H-002 | Phase 2 Clinical | Nanjing Hongyun Biological Technology Co Ltd | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Tomuzotuximab | GT-MAB-5.2-GEX | Phase 1 Clinical | Glycotope Gmbh | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
Izalontamab brengitecan | BL-B01D1 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Nasopharyngeal Carcinoma; Uterine Cervical Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Metastatic breast cancer; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Solid tumours; Digestive System Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Fibroepithelial | Details |
SYS-6010 | SYS6010; SYS-6010 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Solid tumours | Details |
BDTX-1535 | BDTX-1535 | Phase 2 Clinical | Black Diamond Therapeutics Inc | Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
[14C]-PLB1004 | [14C]-PLB1004 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
GC-1118A | GC-1118; GC-1118A | Phase 2 Clinical | GC Biopharma Corp | Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
Cetuximab biosimilar (AMPO Biotechnology) | Phase 3 Clinical | Ampo Biotechnology Inc | Colorectal Neoplasms | Details | |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
FPI-2053 | FPI-2053 | Phase 1 Clinical | Fusion Pharmaceuticals Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
[111In] Panitumumab | Phase 1 Clinical | Stanford University | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
EGFR IL12 CART | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
WJ-13404 | WJ-13404; JS-113; WJ-004 | Phase 2 Clinical | Wigen Biomedicine technology (Shanghai) Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Cetuximab biosimilar (Guilin Sanjin) | CDP-1; BC-001 | Phase 1 Clinical | Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
Serclutamab talirine | ABBV-321 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
BEBT-109 | BEBT-109 | Phase 3 Clinical | Guangzhou BeBetter Medicine Technology Co | Carcinoma, Non-Small-Cell Lung | Details |
ZN-e4 | ZN-e4; KP-673 | Phase 2 Clinical | Zentalis Pharmaceuticals LLC, Zeno Pharma | Carcinoma, Non-Small-Cell Lung | Details |
NX-019 | NX-019 | Phase 1 Clinical | Nalo Therapeutics Inc | Neoplasms | Details |
QLH-11811 | QLH-11811; QLH11811 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
TQB3804 | TQB-3804 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Immunomodulatory progenitor cell therapy (Celixir) | Phase 3 Clinical | Celixir | Endomyocardial Fibrosis; Cardiomyopathies | Details | |
HSK-40118 | HSK40118; HSK-40118 | Phase 1 Clinical | Haisco Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
C225-ILS-DOX | C225-ILs-dox | Phase 2 Clinical | Universitaetsspitals Basel | Breast Neoplasms | Details |
AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
HER-1 vaccine (Center of Molecular Immunology) | HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP | Phase 2 Clinical | Center Of Molecular Immunology | Neoplasms | Details |
AZD9592 | AZD-9592; AZD9592 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Hemay-020 | Hemay-020 | Phase 1 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
WTS-004 | WTS-004 | Phase 1 Clinical | Hangzhou Wutong Tree Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
Olafertinib | CK-101; RX-518; CS-2481; EGFR-IN-3 | Phase 3 Clinical | Suzhou Neupharma Co Ltd | Lung Diseases; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
DBPR-112 | ABT-101; DBPR-112 | Phase 2 Clinical | National Health Research Institutes | Solid tumours; Head and Neck Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BLU-701 | BLU-701; BLU 701 | Phase 1 Clinical | Blueprint Medicines Corp | Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
FCN-411 | FCN-411 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Losatuxizumab vedotin | ABBV-221; ABBV221 | Phase 1 Clinical | Abbvie Inc | Neoplasms | Details |
Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) | Phase 1 Clinical | Harbin Pharmaceutical Group Holding Co Ltd | Colorectal Neoplasms | Details | |
BPI-15086 | BPI-15086; BPI-15000 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
CPO-301 | CPO301; CPO-301 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours; Neoplasms; Lung Neoplasms | Details |
JY-016 | JY-016 | Phase 1 Clinical | Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd | Solid tumours; Colorectal Neoplasms; Lung Neoplasms | Details |
SNC109 | SNC109; SNC-109 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Glioblastoma | Details |
KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
ORIC-114 | ORIC-114; VRN-07 | Phase 2 Clinical | Voronoi Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Antibody-drug nanocell conjugates (EnGeneIC) | EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox | Phase 1 Clinical | Engeneic Ltd | Glioblastoma | Details |
ABY-029 | ABY-029 | Phase 1 Clinical | Dartmouth College, Affibody Ab, Li-Cor Bioscience | Head and Neck Neoplasms; Sarcoma; Glioma | Details |
EGFRvIII-CAR | Phase 1 Clinical | Duke University Medical Center | Glioblastoma | Details | |
Cetuximab biosimilar (AlphaMab) | KN-005 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms | Details |
Double-deleted Vaccinia Virus Plus CD/ SMR | JX-929; vvDD-CDSR | Phase 1 Clinical | Sillajen Inc | Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma | Details |
Simotinib Hydrochloride | AL-6802; SIM-6802 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Advenchen Laboratories Llc | Carcinoma, Non-Small-Cell Lung | Details |
EG-007 | EG-007 | Phase 3 Clinical | Evergreen Therapeutics Inc | Endometrial Neoplasms | Details |
GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
ZZ-06 | ZZ-06 | Phase 1 Clinical | Changchun Intellicrown Pharmaceutical Co Ltd | Solid tumours | Details |
Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) | Phase 2 Clinical | Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd | Colorectal Neoplasms | Details | |
HS-10375 | HS-10375 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
EGFR/B7H3 CAR-T | EGFR/B7H3 CAR-T | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Triple Negative Breast Neoplasms; Lung Neoplasms | Details |
Demupitamab | SCT-200 | Phase 2 Clinical | SinoCelltech Ltd | Ovarian Neoplasms; Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Becotatug | JMT-101 | Phase 3 Clinical | Shanghai Jmt-Bio Inc | Solid tumours; Rectal Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
NIP-142 | NIP-142 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
SYN-004 (Synermore Biologics) | LR-004; SYN-004 | Phase 1 Clinical | Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd | Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Colorectal Neoplasms | Details |
LY-01010 | LY-01010 | Phase 1 Clinical | Luye Pharma Group Ltd | Breast Neoplasms | Details |
Pimurutamab | HLX-07 | Phase 2 Clinical | Shanghai Henlius Biotech Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Adenosquamous; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Futuximab/Modotuximab | Sym-004; S95026; S-95026; 992-and-1024 | Phase 2 Clinical | Symphogen A/S | Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Glioma | Details |
ES-072 | ES-072 | Phase 1 Clinical | Zhejiang Bosheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
ZSP-0391 | ZSP-0391 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
PLB-1004 | PLB-1004 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
QRH-882260 | QRH-882260 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details |
TRX-221 | TRX-221 | Phase 2 Clinical | Therapex Corp | Carcinoma, Non-Small-Cell Lung | Details |
ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
NRC-2694 | NRC-2694; NRC-2694A; NRC-2694-A | Phase 2 Clinical | Natco Pharma | Carcinoma; Squamous Cell Carcinoma of Head and Neck | Details |
Tarloxotinib Bromide | PR-610; TH-4000; SN-33999 | Phase 2 Clinical | Threshold | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung | Details |
14C-labeled poziotinib | Phase 1 Clinical | Spectrum Pharmaceuticals | Solid tumours | Details | |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
BB-101 (Blue Blood Biotech/National Cheng Kung University) | BB-101 | Phase 1 Clinical | National Cheng Kung University, Blue Blood Biotech Corp | Diabetic Foot | Details |
Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
BB-401 | BB-401 | Phase 2 Clinical | Benitec Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | Details |
FPI-2068 | FPI-2068 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
SMET-12 | SMET-12 | Phase 2 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
Cetuximab biosimilar (Humanwell Healthcare) | Phase 1 Clinical | Humanwell Healthcare (Group) Co Ltd | Colorectal Neoplasms | Details | |
Lifirafenib | BeiGene-283; BGB-283 | Phase 1 Clinical | Beigene Ltd | Solid tumours | Details |
Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Neptinib Di-P-methylbenzenesulfonate | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
E-EDV-D682 | PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 | Phase 2 Clinical | Engeneic Ltd | Pancreatic Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
[89Zr]Panitumumab | Phase 1 Clinical | Vanderbilt-Ingram Cancer Center, University Of Alabama At Birmingham, Stanford University | Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Pancreatic Neoplasms | Details | |
Cetuximab biosimilar (Shanghai Henlius Biotech) | HLX-05; JZB-29; JZB-28 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms | Details |
Anti-EGFR CAR-T cell therapy (Beijing Pregene) | Phase 2 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Colorectal Neoplasms | Details | |
M-1231 | M-1231 | Phase 1 Clinical | Emd Serono Research & Development Institute Inc, Merck Serono | Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Ametumumab | SY-101 | Phase 2 Clinical | Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd | Solid tumours; Colorectal Neoplasms | Details |
DWP-708 | DWP-708 | Phase 2 Clinical | Daewoong Pharmaceutical Co Ltd | Acneiform Eruptions | Details |
Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) | CPGJ-602; 602; CPGJ602; CPGJ 602 | Phase 2 Clinical | Colorectal Neoplasms | Details | |
Petosemtamab | MCLA-158 | Phase 2 Clinical | Merus Nv | Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) | Phase 1 Clinical | Zhejiang Xinweishengke Biotechnology Co Ltd | Esophageal Neoplasms | Details | |
Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Agerafenib hydrochloride | RXDX-105; AC013773; CEP-32496 | Phase 1 Clinical | Teva, Daiichi Sankyo Co Ltd, Ambit Biosciences Co, Cephalon | Solid tumours | Details |
CMAB-017 | CMAB-017 | Phase 1 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Solid tumours | Details |
TQ-B3395 | TQ-B3395; CT-1495; TQ-B-3395 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Neoplasms; Breast Neoplasms | Details |
IAE-0972 | IAE-0972 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.